BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28718423)

  • 1. Angiogenesis and Metabolism: Entwined for Therapy Resistance.
    Jiménez-Valerio G; Casanovas O
    Trends Cancer; 2017 Jan; 3(1):10-18. PubMed ID: 28718423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy.
    Rey S; Schito L; Wouters BG; Eliasof S; Kerbel RS
    Trends Cancer; 2017 Jul; 3(7):529-541. PubMed ID: 28718406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications.
    Quintieri L; Selmy M; Indraccolo S
    Biochem Pharmacol; 2014 May; 89(2):162-70. PubMed ID: 24607274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the tumor stroma in cancer therapy.
    Anton K; Glod J
    Curr Pharm Biotechnol; 2009 Feb; 10(2):185-91. PubMed ID: 19199950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed.
    Qin L; Bromberg-White JL; Qian CN
    Adv Cancer Res; 2012; 113():191-239. PubMed ID: 22429856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The great escape; the hallmarks of resistance to antiangiogenic therapy.
    van Beijnum JR; Nowak-Sliwinska P; Huijbers EJ; Thijssen VL; Griffioen AW
    Pharmacol Rev; 2015; 67(2):441-61. PubMed ID: 25769965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
    Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
    Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapies: going beyond their limits.
    Moserle L; Jiménez-Valerio G; Casanovas O
    Cancer Discov; 2014 Jan; 4(1):31-41. PubMed ID: 24356098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
    Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
    Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor angiogenesis revisited: Regulators and clinical implications.
    Ronca R; Benkheil M; Mitola S; Struyf S; Liekens S
    Med Res Rev; 2017 Nov; 37(6):1231-1274. PubMed ID: 28643862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
    Simon T; Gagliano T; Giamas G
    Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of anti-angiogenic therapy in tumors.
    Zulato E; Curtarello M; Nardo G; Indraccolo S
    Biochimie; 2012 Apr; 94(4):925-31. PubMed ID: 22245704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.
    Rapisarda A; Melillo G
    Nat Rev Clin Oncol; 2012 Apr; 9(7):378-90. PubMed ID: 22525710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
    Qian CN; Tan MH; Yang JP; Cao Y
    Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance.
    Iwamoto H; Abe M; Yang Y; Cui D; Seki T; Nakamura M; Hosaka K; Lim S; Wu J; He X; Sun X; Lu Y; Zhou Q; Shi W; Torimura T; Nie G; Li Q; Cao Y
    Cell Metab; 2018 Jul; 28(1):104-117.e5. PubMed ID: 29861385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.
    Pinto MP; Sotomayor P; Carrasco-Avino G; Corvalan AH; Owen GI
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research.
    Jiménez-Valerio G; Casanovas O
    Curr Drug Targets; 2016; 17(15):1728-1734. PubMed ID: 26926466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.